Mesothelioma Cancer Resources Blog
-
FDA Grants Breakthrough Therapy Designation to Drug Targeting Biomarker Found in Lung Cancer and Mesothelioma Patients
Boehringer Ingelheim announced last month that the U.S. Food and Drug Administration has granted Breakthrough Therapy Designation to its investigational cancer drug BI 1482694 for the treatment of non-small cell lung cancer (NSCLC). According to Boehringer Ingelheim, the maker of 1482694, the drug is targeted to NSCLC patients whose tumors have epidermal growth factor (EGFR) …
Label: Featured Story
Posted on Tuesday, Jan 12, 2016
Mike is a licensed attorney and the former editor of North Carolina Lawyers Weekly and South Carolina Lawyers Weekly. He has contributed numerous articles to the North Carolina State Bar Journal and is a co-author of Capital Lawyers, a history of the Wake County (NC) Bar.
Gregory Froom is a licensed North Carolina attorney and the former editor of North Carolina Lawyers Weekly and South Carolina Lawyers Weekly.
Nancy is a blog writer with more than 20 years of professional experience in the Information Technology industry. She lives in Wake Forest, N.C.